Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3b extension study of guselkumab in Crohn's disease
MOH_2026-08-09_016970Phase 3Active, not recruiting
- Sponsor
- פרופ' ויסאם סבית
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of guselkumab in Crohn's disease, sponsored by פרופ' ויסאם סבית. Started Jul 2026; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2026-08-09_016970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-09_016970.